Related Experiment Video
Updated: Aug 17, 2026

Development of Leishmania Species Strains with Constitutive Expression of eGFP
Published on: April 21, 2023
Developments in the treatment of leishmaniasis and trypanosomiasis
Piero Olliaro1, Janis Lazdins, Felipe Guhl
1UNDP, World Bank, World Health Organisation Special Programme for Research and Training in Tropical Diseases, TDR, Geneva, Switzerland. olliarop@who.int
Abstract:
The leishmaniases and trypanosomiases are diseases caused by related parasites belonging to the kinetoplastidae family. They share common biological traits, which are comparatively better known than for other parasites, and which would favour the identification of common targets. Yet, very few new drugs are on the horizon and treatment relies on old, often toxic and ineffective drugs. Miltefosine may soon become the first oral drug registered for Leishmaniasis. Other compounds in clinical trials are paromomycin, sitamquine and lipid formulations of amphotericin B. For African trypanosomiasis old drugs primarily indicated for Chagas disease are being considered (nifurtimox, megazole). Earlier projects are berenil, bisamidines and triazines for African trypanosomiasis, and novel azoles and cruzipain inhibitors for Chagas disease.
More Related Videos
11:36Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis
American Trypanosomiasis
Anthelminthic Agents
Malaria
Trichomoniasis